IMPROVE-IT’s Mixed Blessing: How Low Does LDL Really Need To Go?

 
• By Emily Hayes

Sponsors of injectable PCSK9 biologics address questions about the implications of the IMPROVE-IT study, in which the soon-to-be-generic oral Zetia helped bring down LDL cholesterol to a very low level.

The surprisingly positive result of the IMPROVE-IT study bodes well for LDL cholesterol as a surrogate for better cardiovascular outcomes, but also raises questions about how low to push this marker and how much benefit is achieved.

Results from the IMPROVE-IT study of Merck & Co. Inc.’s oral cholesterol transport inhibitor ezetimibe (single agent Zetia and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D